User:Breddoch/sandbox

Sulopenem/sulopenem etzadroxil-probenecid is an oral pro drug carbapenem under development for the treatment of drug resistant organisms including: ESBL, and N. gonorrhoeae in the setting of of Uncomplicated Urinary Tract Infection. Sulopenem as a carbapenem is broad spectrum and possesses activity against anaerobes, gram positive and gram negative pathogens. It is marketed by Iterum Therapeutics . The drug is being tested with the goal of being able to treat community acquired pneumonia, prostatitis, pelvic inflammatory disease, complicated intraabdominal infections with an easy transition from intravenous carbapenem antibiotics commonly used in the healthcare setting.

Microbiology
Broad spectrum similar to currently used carbapenems, but lacks coverage against Pseudomonas similar to ertapenem.

Pharmacology
Sulopenem a beta-lactam carbapenem class antibiotic, and probenecid a urocosuric agent which reduces the excretion of sulopenem. Sulopenem is resistant to many beta-lactamases.

Regulatory approvals
Sulopenem/sulopenem etzadroxil-probenecid is not currently FDA approved for use in the United States.